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Abstract
Background: Plasma total homocysteine (tHcy) is commonly elevated in persons with diabetes.
This may be due to effects of insulin and/or glucose and/or metabolic control on the metabolism
or plasma levels of tHcy. This study examined the effects of fasting plasma glucose status on fasting
tHcy levels among adults without diabetes, and diabetes per se among adults with a self-report
history of diabetes.
Methods: Analysis of data on adults (≥  20y) who had fasted at least 8 hours, from the National
Health and Nutrition Examination Survey (1999–2000 and 2001–2002). Subjects with no self-
report history of diabetes were grouped according to fasting plasma glucose status as normal (<
100 mg/dL = NFG, n = 2,244), impaired (≥  100 < 126 mg/dL = IFG, n = 1,108), or a provisional
diagnosis of diabetes (≥  126 mg/dL = DFG, n = 133). Subjects with a self-report history of diabetes
(n = 275) were examined separately.
Results: Fasting tHcy was higher (Ps < 0.01) among non-diabetic subjects with DFG and IFG,
compared to NFG (median [95% confidence interval] = 8.6 [8.0–9.2], 8.3 [8.1–8.5], and 7.4 [7.3–
7.5] µmol/L, respectively). Diabetic subjects had levels similar to non-diabetic subjects with DFG
and IFG (8.3 [7.9–8.6] µmol/L). Age and estimated creatinine clearance were strong correlates of
fasting tHcy among non-diabetic subjects (r = 0.38 to 0.44 and r = -0.35 to -0.46, respectively) and
diabetic subjects (r = 0.41 and r = -0.46, respectively) (Ps < 0.001), while fasting glucose and
glycohemoglobin (HbA1c) were weaker (but still significant) correlates of tHcy in non-diabetic and
diabetic subjects. Fasting glucose status was not a significant independent predictor of fasting tHcy
levels in non-diabetic subjects, and HbA1c was not a significant independent predictor of tHcy in
diabetic subjects (Ps > 0.05).
Conclusion: Fasting tHcy levels are elevated among non-diabetic adults with elevated fasting
glucose levels, compared to persons with normal fasting glucose levels, and among diabetic adults.
However, elevations in fasting tHcy appear to be mediated primarily by age and kidney function,
and not by measures of glucose metabolism.
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Background
Clinical studies have established that individuals with dia-
betes have a two- to six-fold increased risk for various
manifestations of cardiovascular disease (CVD), com-
pared to age matched nondiabetic subjects [1-3].
Although individuals with diabetes have a higher preva-
lence of traditional CVD risk factors (e.g., hypertension
and dyslipidemia) compared to nondiabetics, these risk
factors do not fully account for the excess mortality asso-
ciated with diabetes [4]. Even before the clinical diagnosis
of type 2 diabetes, a significantly elevated risk of CVD was
found in a large cohort of women in the U.S. who subse-
quently developed diabetes compared to women who
remained nondiabetic [5]. Thus, having diabetes is an
established independent risk factor for the development
of CVD.
In an early meta-analysis assessing the relationship
between plasma total homocysteine (tHcy) and CVD [6],
it was reported that elevated tHcy was strongly and inde-
pendently related to several manifestations of CVD in the
general population. Subsequent meta-analyses have con-
firmed the significant relationship between tHcy and CVD
risk in healthy populations [7,8], although the strength of
association in these studies was weaker than reported pre-
viously. These meta-analyses were based on studies in
healthy populations, thus, the relationship between tHcy
and CVD risk in subjects with a disease highly related to
CVD risk itself, such as diabetes, is largely unknown. In a
large cohort of 50–75y men from the Netherlands [9], the
risk for any CVD was increased with a parallel elevation in
tHcy across subjects stratified by glucose tolerance – from
normal glucose tolerance to impaired glucose tolerance to
type 2 diabetes – even after adjustment for traditional
CVD risk factors and serum creatinine. In a prospective
analysis of this cohort, elevated tHcy was related to 5-year
mortality [10] and coronary events [11] in subjects with
type 2 diabetes, independent of other CVD risk factors. In
these studies, elevated tHcy was a stronger risk factor for
CVD in diabetic than in nondiabetic individuals.
It is unknown why tHcy is elevated in persons with diabe-
tes. Elevated tHcy was more common in patients with
complications of type 2 diabetes, compared to patients
with uncomplicated disease and controls [12]. Increased
tHcy was also reported in patients with poorly controlled
type 2 diabetes, compared to well controlled patients and
matched controls in a clinic based study in Poland [13].
Results of a recent prospective study in an older cohort of
Italian adults [14] demonstrated that tHcy was decreased
in patients with type 2 diabetes who had a modest
improvement in metabolic control (assessed by glycohe-
moglobin, HbA1c), whereas tHcy increased in subjects
who had an increase in HbA1c and was unchanged in
patients who had no change in HbA1c. Poor metabolic
control was also associated with elevated tHcy levels in
patients with type 1 diabetes [15], consistent with studies
in which lower tHcy levels were reported for well control-
led, insulin-treated type 1 diabetics than in controls [16].
Together, these studies suggest that tHcy levels in persons
with diabetes may be at least partially related to metabolic
control. Similarly, in-vitro  evidence demonstrates that
important enzymes of intracellular homocysteine metab-
olism were directly regulated by insulin and glucose con-
centrations [17]. This study tested the hypothesis that
fasting plasma glucose status independently predicts fast-
ing tHcy in a large, representative sample of non-diabetic
U.S. adults. This study also examined correlates of fasting
tHcy among a large sample of U.S. adults with a self-
report history of diabetes.
Methods
This report is based on data from the combined 1999–
2000 and 2001–2002 National Health and Nutrition
Examination Survey (NHANES). The study design is a
stratified, multistage probability sample of the civilian
non-institutionalized U.S. population. Approximately
9,965 persons aged 2 months to 85 years were studied in
NHANES 1999–2000, and 11,039 in NHANES 2001–
2002. A sub sample of over 3,000 individuals from each
survey was invited to attend a morning examination after
having fasted overnight. The data collection procedure
involved an initial home interview component comprised
of a screener, sample person, and family interview ques-
tionnaire. All interviewed persons were then invited to
complete the health examination component of the sur-
vey in a mobile examination center, which included a
series of health questionnaires, a physical examination,
and a laboratory component. Fully informed consent was
obtained from all participants as approved by the
National Center for Health Statistic's Institutional Review
Board.
Details of the NHANES protocol are available elsewhere.
Briefly, height was measured in an upright position with a
stadiometer, and weight at a standing position on a self-
zeroing scale. Blood pressure measurements were per-
formed by trained technicians using a standardized proto-
col. Three and sometimes four measurements were made
on all subjects with a mercury sphygmomanometer, and
the first and fifth Korotkoff sounds were recorded to rep-
resent the systolic and diastolic pressures. We used the
average of three recorded measurements in all data analy-
ses. Blood analytes were stored under appropriate frozen
conditions until they were shipped to a central laboratory
for analysis. Plasma tHcy was measured using a floures-
cence polarization immunoassay (Abbott Diagnostics).
Plasma glucose was measured using an enzymatic tech-
nique employing the hexokinase/glucose-6-phospate
dehyrogenase reaction. Glycohemoglobin was measuredNutrition & Metabolism 2005, 2:13 http://www.nutritionandmetabolism.com/content/2/1/13
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in whole blood using a fully automated glycohemoglobin
analyzer (Primus Instruments) and boromate affinity
high-performance liquid chromatography. Total choles-
terol was measured in serum or plasma using an enzy-
matic technique. Serum levels of folate and vitamin B12
were measured using a radioassay kit (Bio-Rad Laborato-
ries), and serum creatinine was measured using a photo-
metric method employing the Jaffe reaction. Creatinine
clearance was estimated (CCr) using the Cockcroft-Gault
formula [18].
Data from each survey were linked using the unique sur-
vey participant identifier (SEQN). The primary analyses
consisted of 3,485 adults (20–85y) with a fasting (at least
8 hours) plasma glucose value recorded and who
responded "No" to a lead-in question on diabetes history
(see below). Subjects with a fasting plasma glucose < 100
mg/dL were categorized as having normal fasting glucose
(NFG), those with a value ≥  100 < 126 mg/dL as having
impaired fasting glucose (IFG), and those with a level ≥
126 mg/dL as having a provisional diagnosis of diabetes
(DFG) [19]. The second set of analyses consisted of 275
adults (20–85y) based on a personal interview on diabe-
tes, including use of medications and symptoms associ-
ated with diabetes. All subjects were asked a lead-in
question pertaining to history of diabetes ("Have you ever
been told by a doctor or health professional that you have
diabetes or sugar diabetes?"). Subjects with a missing
response, those who refused to respond, and those who
responded "No", "Don't know", or "Borderline" were
excluded from these analyses. Pregnant females were also
excluded from both sets of analyses.
Statistical Analysis
Data were analyzed using SAS (Version 9.1) survey proce-
dures. Both analyses used the four-year fasting weights
(WTSFA4YR) to estimate means and 95% confidence
intervals, and the masked variance units (pseudo-primary
sampling units [SDMVPSU] and pseudo-stratum [SDM-
VSTRA]) to estimate standard errors of those means. Con-
tinuous variables were analyzed using PROC
SURVEYMEANS and are presented as a mean (± standard
error). Categorical variables were analyzed using PROC
SURVEYFREQ and are presented as a frequency (n),
weighted frequency (based on sampling weights), and
proportion [with 95% confidence interval]. Proportions
are based on a percentage of the weighted frequencies.
Differences in continuous variables were tested univari-
ately using the t-test for independent samples (using
PROC SURVEYREG), and prevalence values for categori-
cal variables were compared using the χ 2 test for propor-
tions (in PROC SURVEYFREQ). Statistical significance
was established at α  = 0.05 a priori, and multiple compar-
isons were adjusted using the Bonferroni method.
Results
The primary analyses included a sample of 3,485 adults.
By definition (see Methods section), none of these subjects
had a self-report history of diabetes, and none reported
taking insulin or diabetic pills to lower blood sugar. The
sex distribution was roughly 50% male and female, and
race distribution 24% Mexican-American, 5% other His-
panics, 51% non-Hispanic white, 18% non-Hispanic
black, and 3% other (including multicultural). Using pop-
ulation-based sample weights, this was equivalent to a
population of 179,557,944 adults 45.5 ± 0.6y with sex
distribution 49% male and 51% female, and race distribu-
tion 7% Mexican-American, 6% other Hispanics, 73%
non-Hispanic white, 10% non-Hispanic black, and 4%
other. There were 114 subjects in this sample with a self-
report of coronary heart disease (CHD) and 91 with a self-
report of stroke, equivalent to less than 3% of this popu-
lation with CHD or stroke.
Differences in physiological variables by fasting glucose
status are presented in Table 1. Age, tHcy, glucose, HbA1c,
insulin, BMI, and systolic blood pressure were signifi-
cantly higher in IFG and DFG groups than the NFG group
(Ps < 0.017). In addition, total cholesterol and serum cre-
atinine were higher (Ps < 0.017) in IFG than NFG. Further-
more, age, glucose, HbA1c, insulin, BMI, and systolic
blood pressure were higher in DFG than IFG (Ps < 0.017).
There were no differences (P > 0.05) among groups with
respect to vitamin status (serum folate and B12) and CCr,
although the comparison between DFG and IFG with
respect to CCr just missed significance (P = 0.02, adjusted
α  = 0.17).
Correlations between tHcy and physiologic variables, by
fasting glucose status, are shown in Table 2. In the total
sample, age (r = 0.41) and CCr (r = -0.38) were the strong-
est correlates of tHcy (Ps < 0.0001). This was consistent
when correlates of tHcy were examined by individual
groups, with correlations for age ranging from r = 0.38 to
0.44, and for CCr ranging from r = -0.35 to -0.46 (Ps <
0.001). Glucose and HbA1c were weaker, but still signifi-
cant, correlates of tHcy in all subjects (r = 0.12 and 0.10,
Ps < 0.0001), and in NFG (r = 0.11 and 0.12, Ps < 0.0001)
and IFG groups (r = 0.15 and 0.07, Ps < 0.05). In contrast
to the other groups, there was a negative relationship
between tHcy and glucose (r = -0.14), and tHcy and HbA1c
(r  = -0.19), with only the latter being significant (P  <
0.05).
Results from univariate and multivariate regression mod-
els are presented in Table 3. Fasting glucose status was a
significant predictor of tHcy (Model 1, Ps < 0.001). How-
ever, after adjusting for demographic and physiologic var-
iables that influence homocysteine metabolism and/or
fasting tHcy concentrations, fasting glucose status was noNutrition & Metabolism 2005, 2:13 http://www.nutritionandmetabolism.com/content/2/1/13
Page 4 of 8
(page number not for citation purposes)
longer a significant predictor (Models 2 and 3, Ps > 0.05).
Next, fasting glucose status was examined after adjusting
for age, sex, and a measure of kidney function only. Simi-
lar to previous findings, fasting glucose status was not a
significant predictor when serum creatinine was included
in the model (Model 4, Ps > 0.05). However, fasting glu-
cose status was a significant predictor when CCr  was
included in the model (Model 5, Ps < 0.05). HbA1c was a
significant predictor of tHcy in the model using CCr as the
measure of kidney function (Model 3, P < 0.05), but not
in the model using serum creatinine (Model 2, P > 0.05).
The analyses completed on subjects by self-report diabetes
history included a sample of 275 adults, with an equal sex
distribution, 34% Mexican-American, 7% other Hispan-
ics, 36% non-Hispanic white, 19% non-Hispanic black,
and 4% other (including multicultural). Using popula-
tion-based sample weights, this was equivalent to a
population of 12,322,266 adults 56.5 ± 1.1y with sex dis-
tribution 45% female and 55% male, and race distribu-
tion roughly 8% Mexican-American, 9% other Hispanics,
62% non-Hispanic white, 13% non-Hispanic black, and
8% other. Thirteen subjects (5% of this population)
reported taking insulin, and 205 subjects (67%) reported
use of diabetic pills to lower blood sugar. There were 28
subjects in this sample with a self-report of CHD and 13
with a self-report of stroke (about 8% of this population
had CHD and 3.6% had stroke). The median tHcy level
was 8.3 [7.9–8.6] µmol/L, and the average physiologic
values were the following: fasting plasma glucose 154.6 ±
Table 1: Select physiologic variables by fasting plasma glucose status among 3,485 U.S. adults (≥  20y) with no self-reported diabetes.
Variable NFG (n = 2,244) IFG (n = 1,108) DFG (n = 133)
tHcy (µmol/L) 7.4 [7.3–7.5] 8.3 [8.1–8.5]* 8.6 [8.0–9.2]†
Age (years) 42.3 ± 0.6 52.1 ± 0.7* 58.2 ± 2.3†‡
Glucose (mg/dL) 90.8 ± 0.2 106.9 ± 0.2* 170.8 ± 8.5†‡
HbA1c (%) 5.2 ± 0.0 5.5 ± 0.0* 7.2 ± 0.3†‡
Insulin (uU/mL) 9.8 ± 0.1 14.1 ± 0.4* 26.4 ± 1.9†‡
BMI (kg/m2) 26.7 ± 0.1 29.3 ± 0.2* 33.5 ± 1.3†‡
SBP (mmHg) 120.5 ± 0.6 127.5 ± 0.6* 135.7 ± 2.8†‡
TC (mg/dL) 198.9 ± 1.4 209.8 ± 1.6* 211.2 ± 5.9
Folate (ng/mL) 14.1 ± 0.3 14.5 ± 0.3 14.4 ± 0.9
Vitamin B12 (pg/mL) 492.2 ± 4.2 486.0 ± 8.5 486.5 ± 20.9
Creatinine (µmol/L) 68.4 ± 0.8 75.9 ± 2.4* 72.2 ± 2.9
CCr (mL/min) 131.6 ± 1.9 126.5 ± 2.5 142.5 ± 10.4
Data are from the combined 1999–2000 and 2001–2002 National Health and Nutrition Examination Surveys. Non-standard abbreviations are NFG, 
normal fasting glucose, IFG, impaired fasting glucose, DFG, provisional diagnosis of diabetes, tHcy, total plasma homocysteine, SBP, systolic blood 
pressure, TC, total lipoprotein cholesterol, and CCr, estimated creatinine clearance. Values are mean ± standard error, except for tHcy, which was 
log transformed because of its highly skewed distribution and is presented as median with 95% confidence interval (antilog values).
*P < 0.017 for NFG vs. IFG
† P < 0.017 for NFG vs. DFG
‡ P < 0.017 for IFG vs. DFG
Table 2: Relationships between total plasma homocysteine and select physiologic variables, by fasting glucose status, among 3,485 U.S. 
adults (≥  20y) with no self-reported diabetes.
Group Age Glucose HbA1c Insulin BMI SBP TC Folate B12 SCr CCr
Total 0.41* 0.12* 0.10* -0.00 -0.01 0.28* 0.11* -0.10* -0.25* 0.35* -0.38*
NFG 0.38* 0.11* 0.12* -0.05‡ -0.02 0.30* 0.14* -0.15* -0.24* 0.34* -0.35*
IFG 0.38* 0.15* 0.07‡ -0.06 -0.07‡ 0.19* -0.01 -0.05 -0.26* 0.32* -0.42*
DFG 0.44* -0.14 -0.19‡ -0.21‡ -0.19‡ 0.13 0.05 0.15 -0.28† 0.55* -0.46*
Data are from the combined 1999–2000 and 2001–2002 National Health and Nutrition Examination Surveys. Non-standard abbreviations are NFG, 
normal fasting glucose, IFG, impaired fasting glucose, DFG, provisional diagnosis of diabetes, SBP, systolic blood pressure, TC, total lipoprotein 
cholesterol, SCr, serum creatinine, and CCr, estimated creatinine clearance. Values are Pearson correlation coefficients (r) using log transformed 
total homocysteine (log tHcy) as the dependent variable.
*P < 0.0001
†P < 0.01
‡P < 0.05Nutrition & Metabolism 2005, 2:13 http://www.nutritionandmetabolism.com/content/2/1/13
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3.6 mg/dL, HbA1c 7.2 ± 0.1%, fasting insulin 20.7 ± 1.7
uU/mL, BMI 31.4 ± 0.8 kg/m2, systolic blood pressure
131.7 ± 1.2 mmHg, total cholesterol 199.2 ± 2.6 mg/dL,
serum folate 15.2 ± 0.8 ng/mL and vitamin B12 548.3 ±
22.4 pg/mL, serum creatinine 73.6 ± 3.2 µmol/L, and CCr
138.7 ± 7.3 mL/min.
Similar to findings among non-diabetic subjects, age (r =
0.41) and CCr (r = -0.46) were the strongest correlates of
tHcy (Ps  < 0.0001), whereas glucose and HbA1c were
weaker, but still significant, correlates of tHcy (r = -0.15
and -0.17, Ps < 0.05). Finally, results from univariate and
multivariate regression models among subjects with a
self-report history of diabetes are presented in Table 4. In
the full models (1 and 2), measures of kidney function
(either serum creatinine or CCr) were again the strongest
predictors of tHcy, whereas neither HbA1c nor insulin
were significant predictors of tHcy in these models. In
contrast, in the abbreviated models controlling for sex,
age, and a measure of kidney function (models 3 and 4),
serum creatinine was (P < 0.05), but CCr was not, a signif-
icant predictor of tHcy.
Discussion
This study demonstrates that fasting tHcy levels are ele-
vated in non-diabetic subjects as a function of fasting glu-
cose status; tHcy concentrations increased progressively
with worsening fasting glucose. Subjects with self-
reported diabetes had levels similar to levels found in
non-diabetic subjects who had abnormally high fasting
gluocse levels. The difference in fasting tHcy was 1.2
µmol/L between groups representing the extremes of fast-
ing glucose, and 0.9 µmol/L between subjects with a self-
report history of diabetes and those without a self-report
Table 3: Univariate and multivariate linear models predicting total plasma homocysteine among 3,485 U.S. adults (≥  20y) with no self-
reported diabetes.
IFG DFG Sex Age HbA1c Insulin BMI SBP TC Folate B12 SCr CCr
1 0.1181* 0.1462†
2 0.02 0.08 0.1143* 0.0077* -0.03 -0.00 -0.00 0.0012‡ 0.00 -0.0010* -0.0003* 0.0020‡
3 0.02 0.08 0.1598* 0.0047* -0.0307§ -0.00 0.0070‡ 0.0014† 0.00 -0.0010* -0.0003* -0.0021*
4 0.01 0.01 0.1391* 0.0068* 0.0019‡
5 0.0326‡ 0.0551§ 0.1738* 0.0051* -0.0012*
Data are from the combined 1999–2000 and 2001–2002 National Health and Nutrition Examination Surveys. Non-standard abbreviations are NFG, 
normal fasting glucose, IFG, impaired fasting glucose, DFG, provisional diagnosis of diabetes, SBP, systolic blood pressure, TC, total lipoprotein 
cholesterol, SCr, serum creatinine, and CCr, estimated creatinine clearance. Values are regression coefficients (β ) from univariate and multivariate 
linear models using log transformed total homocysteine (log tHcy) as the dependent variable. For simplicity, the intercept term was omitted from 
the table but was significant (P ≤  0.0001) in all models. Normal fasting glucose and female sex were used as reference groups.
*P < 0.0001
† P < 0.001
‡ P < 0.01
§P < 0.05
Table 4: Univariate and multivariate linear models predicting total plasma homocysteine among 275 U.S. adults (≥  20y) with a self-
report history of diabetes.
Sex Age HbA1c Insulin BMI SBP TC Folate B12 SCr CCr
1 -0.07 0.0114* -0.01 -0.00 0.00 0.00 -0.00 -0.00 -0.0004‡ 0.0025†
2 -0.1139† 0.0058‡ -0.01 -0.00 0.0154† 0.00 -0.00 -0.00 -0.00 -0.0022†
3 -0.07 0.0094* 0.0021‡
4 -0.0979‡ 0.0074† -0.00
Data are from the combined 1999–2000 and 2001–2002 National Health and Nutrition Examination Surveys. Non-standard abbreviations are SBP, 
systolic blood pressure, TC, total lipoprotein cholesterol, SCr, serum creatinine, and CCr, estimated creatinine clearance. Values are regression 
coefficients (β ) from univariate and multivariate linear models using log transformed total homocysteine (log tHcy) as the dependent variable. For 
simplicity, the intercept term was omitted from the table but was significant (P ≤  0.0001) in all models. Female sex was used as the reference group.
*P < 0.0001
† P < 0.01
‡ P < 0.05Nutrition & Metabolism 2005, 2:13 http://www.nutritionandmetabolism.com/content/2/1/13
Page 6 of 8
(page number not for citation purposes)
history of diabetes and normal fasting glucose. The clini-
cal significance of such small differences is unknown, par-
ticularly in light of the fact that tHcy levels were within the
normal range (less than 15 µmol/L) in all groups of
subjects.
Although fasting tHcy levels differed as a function of fast-
ing glucose status, results from correlation and multivari-
ate regression analyses were in agreement that age and
kidney function (measured as serum creatinine or esti-
mated CCr) were the major correlates of fasting tHcy con-
centrations among non-diabetic and diabetic individuals.
In contrast, these analyses provided much less support for
the concept that glucose metabolism has a major influ-
ence on fasting tHcy concentrations.
These findings were somewhat surprising, based on previ-
ous reports demonstrating that fasting tHcy levels were
related to metabolic control in patients with type 1 and
type 2 diabetes [13-16]. In a clinic-based study [13], fast-
ing tHcy levels were nearly doubled in poorly-controlled
than well-controlled patients with type 2 diabetes. In a
prospective study [14], fasting tHcy levels decreased in
patients with type 2 diabetes who experienced modest
improvements in metabolic control, whereas fasting tHcy
increased in patients who had worsened metabolic con-
trol over follow-up. Because measures of kidney function
(blood urea nitrogen and serum creatinine) and vitamin
status (serum folate and B12) were within normal clinical
limits at baseline and remained unchanged during follow-
up, these findings imply a direct effect of metabolic con-
trol on fasting tHcy. However, in the present study HbA1c
was only weakly correlated with fasting tHcy in non-dia-
betic subjects, irrespective of fasting glucose status. The
relationship between HbA1c and tHcy was highest in non-
diabetic subjects with normal fasting glucose, and was
negative in those with a provisional diagnosis of diabetes,
which was opposite to the expected direction. Similarly,
HbA1c was weakly and negatively correlated with tHcy in
diabetic subjects. In multivariate regression analyses, age
and measures of kidney function (serum creatinine or
CCr) were the major predictors of fasting tHcy in non-dia-
betic and diabetic subjects, whereas HbA1c was not a sig-
nificant predictor in either group of subjects.
One factor that might explain why the present results dif-
fer from others with respect to the role of metabolic con-
trol on fasting tHcy is that our study includes current data
obtained from a broad cross-section of the U.S. popula-
tion, whereas other studies were conducted in The Neth-
erlands [9-11], Poland [13], and Italy [14]. Differences in
race and/or lifestyle of individuals living in the various
countries represented in these studies may have contrib-
uted to the differential results. In addition, the U.S. insti-
tuted a program of cereal grain fortification in 1998,
whereas the other countries listed do not have a fortifica-
tion practice in place, which could have attenuated fasting
tHcy levels in subjects from the U.S.
The present findings were also somewhat surprising in
that fasting insulin had little influence on fasting tHcy lev-
els. Although relationships between fasting insulin and
fasting tHcy were negative in non-diabetic subjects, which
is in the expected direction, the strength of these correla-
tions was weak, and were essentially non-existent in dia-
betic subjects (data not shown). Furthermore, fasting
insulin was not a significant predictor in any model of
fasting tHcy. This is somewhat in contrast to findings in
which acute hyperinsulinemia led to a decrease in tHcy in
normal subjects, but not in insulin resistant type 2 diabe-
tes patients, suggesting that insulin had a lowering effect
on tHcy, except in the case of patients who were resistant
to this effect of insulin [20]. On the other hand, in support
of the present findings a recent report [21] failed to show
any influence of insulin resistance or degree of metabolic
control on fasting tHcy levels in obese patients with type
2 diabetes patients treated with daily insulin over a one-
month period.
Although the findings with respect to metabolic control
and insulin were somewhat surprising and in contrast to
other studies, what was not surprising was that kidney
function played a major role in modulating fasting tHcy
concentrations. Because many of the studies mentioned
previously only included a single measure of serum creat-
inine, used as a surrogate marker of renal function, esti-
mated CCr was included in the present analyses to provide
a better assessment of the impact of kidney function on
fasting tHcy levels. The rationale for this was that an esti-
mate of glomerular filtration rate is the best measure of
overall kidney function in health and disease [22]. Fur-
thermore, the kidney has substantial tHcy handling and
metabolizing capabilities [23] and thus it is possible that
previous studies did not adequately account for differ-
ences in kidney function by using serum creatinine alone.
The results of the present study support this contention.
For example, estimated CCr was a slightly stronger corre-
late of fasting tHcy than serum creatinine alone in both
diabetic and non-diabetic subjects. In addition, estimated
CCr was a slightly stronger predictor of fasting tHcy in mul-
tivariate models. This is in contrast to a recent report [24]
that fasting tHcy concentrations were closely and inde-
pendently associated with estimated glomerular filtration
rate, but not with serum creatinine, in groups of patients
with type 1 and type 2 diabetes undergoing intensive insu-
lin treatment. On the other hand, the present results are
supported by previous studies, including Stabler and col-
leagues [25], and Davies and colleagues [26], who dem-
onstrated the importance of renal function on modulatingNutrition & Metabolism 2005, 2:13 http://www.nutritionandmetabolism.com/content/2/1/13
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tHcy levels, at least in patients with type 2 diabetes. The
present results also suggest that there is a differential
impact of CCr, compared to serum creatinine, on fasting
tHcy levels. In non-diabetic subjects, fasting glucose status
was a significant predictor of tHcy after adjusting for age,
sex, and CCr, but not when serum creatinine was
substituted for CCr. Likewise, sex and age, but not CCr,
were significant predictors of tHcy in the abbreviated
models (see Models 3 and 4 in Table 4), whereas age and
serum creatinine, but not sex, where significant predictors
of tHcy when serum creatinine was substituted for CCr in
the models.
Some factors inherent to the study design may have con-
tributed to the differential findings in this study compared
to others, including differences in groups with respect to
demographic and health status variables. For example,
among non-diabetic subjects, the normal fasting glucose
group had more females than males (~ 56% vs. 44%),
whereas both the impaired fasting glucose and provi-
sional diagnosis of diabetes groups had more males than
females (~ 60% vs. 40% in both groups). This could have
contributed to the higher tHcy levels in the latter two
groups because fasting tHcy is typically higher in men
than women [27,28]. Furthermore, sex was a significant
predictor of fasting tHcy in all regression models in non-
diabetic subjects.
In light of the differences in sex distribution, separate
regression models were run for women and men to deter-
mine if there were differences in major correlates of fast-
ing tHcy according to sex. Among females, in the full
regression model using serum creatinine, age, insulin,
total cholesterol, folate, B12, and creatinine were signifi-
cant predictors of fasting tHcy. Among males, age, HbA1c,
systolic blood pressure, folate, and B12, but not creatinine,
were significant predictors of fasting tHcy. Among
females, in the full regression model using CCr, age, BMI,
folate, B12, and CCr were significant predictors of tHcy.
Among males, age, HbA1c, systolic blood pressure, folate,
B12, and CCr were significant predictors of tHcy. Differ-
ences between the sexes with respect to major correlates of
tHcy were also apparent in the abbreviated regression
models. Among females, age and creatinine were both sig-
nificant predictors of tHcy. Among males, age, but not cre-
atinine, was a significant predictor of tHcy. Among
females, the overall effect of fasting glucose status, age,
and estimated CCr were significant predictors of tHcy.
Among males, fasting glucose status was not a significant
predictor of tHcy, after adjusting for age and estimated CCr
(both terms were significant).
Second, there were some differences with respect to self-
reported health status among non-diabetic subjects.
Roughly 2% of non-diabetic subjects with normal fasting
glucose had a self-report of CHD, whereas 4% of non-dia-
betic subjects with impaired fasting glucose and 9% with
a provisional diagnosis of diabetes reported CHD. The
same pattern emerged for stroke (about 2%, 3%, and 7%
for normal, impaired, and provisional diagnosis of diabe-
tes groups). Because macroangiopathy [12] has been
shown to impact fasting tHcy, at least in patients with type
2 diabetes, differences in the prevalence of CHD and
stroke may have contributed to the group differences in
tHcy. However, these differences were not so large that
self-reported health status alone would likely account for
differences in fasting tHcy levels among the various
groups of non-diabetic subjects.
The cross-sectional nature of NHANES does not allow for
the determination of the underlying cause(s) of the ele-
vated fasting tHcy levels in non-diabetic subjects with
impaired fasting glucose/a provisional diagnosis of diabe-
tes, or in diabetic subjects. However, results from the var-
ious analyses were consistent in demonstrating the
importance of age and kidney function in modulating
fasting tHcy levels, while providing much less support for
an important role of glucose metabolism in this regard.
The results of this study were also fairly consistent with
those of Russo and colleagues [29], who found that age,
creatinine, vitamin status, sex, smoking, methylene tet-
rahydrofolate reductase (MTHFR) genotype, and systolic
blood pressure were significantly associated with tHcy in
a clinic-based study of Italian adults with type 2 diabetes.
Similarly, that study found no significant associations
between tHcy and diabetes-related variables, such as dia-
betes duration, fasting glucose, HbA1c, current treatment
regimen, and diabetes complications. Although data on
MTHFR genotype was not available in NHANES, it is
unlikely that large differences existed with respect to gen-
otype distribution among the various groups because the
data were drawn from a large, stratified random sample.
However, this possibility cannot be entirely ruled out.
Conclusion
This study supports the concept that age and kidney func-
tion, and not measures of glucose metabolism (fasting
glucose, level of metabolic control, and insulin), are the
primary correlates of fasting tHcy levels among non-dia-
betic and diabetic adults in the U.S.
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